A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

Recruiting now. Registry record last updated July 22, 2026.

Who can join
Adults 18+, have obesity, BMI 35+.
What you take
KAI-9531, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 2.3 years; your own time in it is usually shorter.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 3Sponsor KaileraDrug KAI-9531Class GLP-1 RASites 27 USEnrollment target 1,200

What this study is for

Primary condition: Obesity.

Full scientific study title: Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do .

Who can join

Age18 and upSexAnyBMI35 or higher

Adults 18+, have obesity, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • BMI ≥35 kilograms per square meter (kg/m\^2).
  • History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

Key exclusion criteria

  • Current diagnosis or history of diabetes mellitus.
  • Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and phentermine.
  • Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
  • Uncontrolled hypertension or unstable cardiovascular disease.

Where this trial is enrolling

This trial has 27 sites across 19 states. Contact a site coordinator directly to start screening.

Arizona2 sites
  • Kailera Clinical Site
    Glendale, Arizona
  • Kailera Clinical Site
    Phoenix, Arizona
Arkansas1 site
  • Kailera Clinical Site
    Little Rock, Arkansas
California2 sites
  • Kailera Clinical Site
    Northridge, California
  • Kailera Clinical Site
    Oceanside, California
Connecticut2 sites
  • Kailera Clinical Site
    Hamden, Connecticut
  • Kailera Clinical Site
    Stamford, Connecticut
Florida1 site
  • Kailera Clinical Site
    Orange City, Florida
Georgia1 site
  • Kailera Clinical Site
    Albany, Georgia
Illinois2 sites
  • Kailera Clinical Site
    Chicago, Illinois
  • Kailera Clinical Site
    Skokie, Illinois
Kansas1 site
  • Kailera Clinical Site
    Newton, Kansas
Louisiana1 site
  • Kailera Clinical Site
    Shreveport, Louisiana
Michigan1 site
  • Kailera Clinical Site
    Farmington Hills, Michigan
Montana1 site
  • Kailera Clinical Site
    Missoula, Montana
Nevada1 site
  • Kailera Clinical Site
    Las Vegas, Nevada
New York1 site
  • Kailera Clinical Site
    Albany, New York
North Carolina2 sites
  • Kailera Clinical Site
    Morehead City, North Carolina
  • Kailera Clinical Site
    Morrisville, North Carolina
Oklahoma1 site
  • Kailera Clinical Site
    Norman, Oklahoma
Rhode Island1 site
  • Kailera Clinical Site
    East Greenwich, Rhode Island
South Carolina2 sites
  • Kailera Clinical Site
    North Charleston, South Carolina
  • Kailera Clinical Site
    Spartanburg, South Carolina
Texas2 sites
  • Kailera Clinical Site
    Brownsville, Texas
  • Kailera Clinical Site
    San Antonio, Texas
Virginia2 sites
  • Kailera Clinical Site
    Manassas, Virginia
  • Kailera Clinical Site
    Richmond, Virginia

Timeline

Started enrolling: December 30, 2025. Expected completion: April 2028. Last updated on ClinicalTrials.gov: July 22, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.